Breaking News Instant updates and real-time market news.

AKCA

Akcea Therapeutics

$22.56

1.45 (6.87%)

07:15
02/07/18
02/07
07:15
02/07/18
07:15

Akcea Therapeutics completes enrollment in Phase 2b study of AKCEA-APO(a)-LRx

Akcea Therapeutics announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-LRx. Akcea is conducting the study in patients with high Lp(a) and established cardiovascular disease, or CVD, to determine the dose level and frequency of administration for a future planned Phase 3 cardiovascular outcome study and to determine the safety and tolerability profile of AKCEA-APO(a)-LRx. Akcea plans to report top-line data from the Phase 2b study in the second half of 2018. Akcea is an affiliate of Ionis Pharmaceuticals Inc. focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

AKCA Akcea Therapeutics
$22.56

1.45 (6.87%)

08/08/17
COWN
08/08/17
INITIATION
COWN
Outperform
Akcea Therapeutics initiated with an Outperform at Cowen
Cowen analyst Eric Schmidt initiated Akcea Therapeutics with an Outperform saying lead candidate volanesorsen, a triglyceride-lowering drug being developed for two rare, severe genetic disorders, Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy, has demonstrated unparalleled potency at reducing serum triglycerides in Phase III trials in patients with severe hypertriglyceridemia. The analyst sees $500M+ in peak sales potential for volanesorsen in Familial Chylomicronemia Syndrome and expects shares to move higher as investors gain conviction in this commercial outlook and the rest of the clinical pipeline.
08/08/17
WELS
08/08/17
INITIATION
Target $27
WELS
Outperform
Akcea Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Akcea Therapeutics with an Outperform rating and $27 price target. The analyst sees potential blockbuster opportunity for the company's lead antisense oligonucleotide therapeutic volanesorsen in patients with familial chylomicronemia syndrome and other severe lipid disorders.
08/08/17
BMOC
08/08/17
INITIATION
BMOC
Outperform
Akcea Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim started coverage of Akcea with a $25 price target and an Outperform rating. The analyst says the company provides "a commercial-ready, rare disease drug opportunity, with a validating partnership lead candidate" at a "small-cap valuation." Kim predicts that the company's volanesorsen, a triglyceride-lowering drug being developed for two rare, severe genetic disorders, Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy, will be approved as a treatment for FCS in 2H18 and generate worldwide peak sales of $800M.
08/08/17
08/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Alphabet (GOOG, GOOGL), and Facebook (FB) were reinstated with a Buy at Mizuho, while eBay (EBAY) and Twitter (TWTR) were reinstated with an Underperform. 2. Broadridge (BR) initiated with a Neutral at DA Davidson. 3. Brighthouse Financial (BHF) initiated with an Overweight at Barclays. 4. Akcea Therapeutics (AKCA) WAS initiated with an Outperform at BMO Capital and Cowen, an Outperform at Wells Fargo, as well as a Buy at Stifel. 5. Lockheed Martin (LMT) and Raytheon (RTN) were initiated with an Overweight at Morgan Stanley, while Northrop Grumman (NOC) was initiated with an Equal Weight, and General Dynamics (GD) was initiated with an Underweight at the firm. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WMT

Walmart

$95.22

-9.56 (-9.12%)

12:21
02/20/18
02/20
12:21
02/20/18
12:21
Recommendations
Walmart analyst commentary  »

Walmart e-commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

WMT

Walmart

$95.23

-9.55 (-9.11%)

, HD

Home Depot

$189.64

2.67 (1.43%)

12:17
02/20/18
02/20
12:17
02/20/18
12:17
General news
On The Fly: Top stock stories at midday »

Stocks opened deep in…

WMT

Walmart

$95.23

-9.55 (-9.11%)

HD

Home Depot

$189.64

2.67 (1.43%)

NXPI

NXP Semiconductors

$118.50

1.58 (1.35%)

QCOM

Qualcomm

$64.85

-0.43 (-0.66%)

AVGO

Broadcom

$248.89

-2.94 (-1.17%)

RAD

Rite Aid

$2.21

0.0801 (3.76%)

MDXG

MiMedx

$14.47

-0.96 (-6.22%)

UBNT

Ubiquiti

$74.04

-1.25 (-1.66%)

VYGR

Voyager Therapeutics

$19.36

0.19 (0.99%)

ABBV

AbbVie

$120.79

2.19 (1.85%)

FOGO

Fogo De Chao

$12.55

-0.15 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 28

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

$NSD

NASDAQ Market Internals

12:17
02/20/18
02/20
12:17
02/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
02/20/18
02/20
12:16
02/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$14.23

0.105 (0.74%)

12:15
02/20/18
02/20
12:15
02/20/18
12:15
Options
Vale put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFII

Electronics for Imaging

$28.11

0.04 (0.14%)

12:10
02/20/18
02/20
12:10
02/20/18
12:10
Conference/Events
Electronics for Imaging management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 13

    Mar

  • 14

    Mar

BHP

BHP Billiton

$46.89

-1.8 (-3.70%)

12:09
02/20/18
02/20
12:09
02/20/18
12:09
Downgrade
BHP Billiton rating change  »

BHP Billiton downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$41.63

-0.51 (-1.21%)

12:05
02/20/18
02/20
12:05
02/20/18
12:05
Options
Mylan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 13

    Nov

12:05
02/20/18
02/20
12:05
02/20/18
12:05
General news
Euro$ interest rate futures are mostly lower »

Euro$ interest rate…

SYNT

Syntel

$26.87

1.16 (4.51%)

12:03
02/20/18
02/20
12:03
02/20/18
12:03
Conference/Events
Syntel management to meet with Loop Capital »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

HSIC

Henry Schein

$69.52

1.14 (1.67%)

12:00
02/20/18
02/20
12:00
02/20/18
12:00
Downgrade
Henry Schein rating change  »

Henry Schein downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

12:00
02/20/18
02/20
12:00
02/20/18
12:00
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

GPS

Gap

$32.18

-1.0899 (-3.28%)

11:58
02/20/18
02/20
11:58
02/20/18
11:58
Recommendations
Gap analyst commentary  »

Jefferies remains buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 18

    Mar

HSIC

Henry Schein

$69.52

1.14 (1.67%)

11:55
02/20/18
02/20
11:55
02/20/18
11:55
Downgrade
Henry Schein rating change  »

Henry Schein downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OZM

Och-Ziff Capital

$2.56

-0.035 (-1.35%)

11:55
02/20/18
02/20
11:55
02/20/18
11:55
Conference/Events
CFA Society of Columbus to hold a luncheon meeting »

Group Luncheon with guest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

DBVT

DBV Technologies

$25.86

-0.29 (-1.11%)

, AIMT

Aimmune

$37.20

-1.04 (-2.72%)

11:54
02/20/18
02/20
11:54
02/20/18
11:54
Recommendations
DBV Technologies, Aimmune analyst commentary  »

DBV Technologies wins…

DBVT

DBV Technologies

$25.86

-0.29 (-1.11%)

AIMT

Aimmune

$37.20

-1.04 (-2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 02

    Mar

  • 11

    Mar

KEYW

KEYW

$7.51

0.01 (0.13%)

11:53
02/20/18
02/20
11:53
02/20/18
11:53
Conference/Events
KEYW management to meet with Maxim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 15

    Mar

  • 14

    Jun

CMCSA

Comcast

$39.79

-0.29 (-0.72%)

, CMCSK

Comcast

11:51
02/20/18
02/20
11:51
02/20/18
11:51
Hot Stocks
NBC ratings down for PyeongChang Olympics »

Comcast's (CMCSA,…

CMCSA

Comcast

$39.79

-0.29 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

ATOS

Atossa Genetics

$0.63

-0.0655 (-9.49%)

11:50
02/20/18
02/20
11:50
02/20/18
11:50
Conference/Events
Atossa Genetics management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

V

Visa

$122.66

0.81 (0.66%)

11:50
02/20/18
02/20
11:50
02/20/18
11:50
Options
Defensive spread opened in Visa »

Defensive spread opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 30

    May

11:50
02/20/18
02/20
11:50
02/20/18
11:50
General news
Treasury's record $96 B 3- and 6-month bill sale saw mixed results »

Treasury's record…

11:45
02/20/18
02/20
11:45
02/20/18
11:45
General news
Treasury Option Action: some call buying in the belly »

Treasury Option Action:…

SNAP

Snap

$19.61

-0.81 (-3.97%)

11:42
02/20/18
02/20
11:42
02/20/18
11:42
Hot Stocks
Snap slides after Citi says sell on redesign concerns »

Shares of Snap (SNAP) are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

LNDC

Landec

$13.90

0.35 (2.58%)

11:41
02/20/18
02/20
11:41
02/20/18
11:41
Conference/Events
Landec management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Mar

  • 21

    Mar

WFC

Wells Fargo

$60.43

0.48 (0.80%)

11:40
02/20/18
02/20
11:40
02/20/18
11:40
Options
Active trading in Wells Fargo options »

Active trading in Wells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

  • 15

    Mar

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.